Skip to Main Content

Paper Details

A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.
Oncologist
4
2021
5-fluorouracil, Eribulin, FAC, FEC, HER2, HER2-Negative Breast Cancer, HER2-negative breast cancer, Paclitaxel, Patients, anthracycline, breast cancer, cyclophosphamide, doxorubicin, epirubicin, eribulin, locally advanced operable, neutropenia, neutropenic fever, neutropenic sepsis, nonmetastatic operable breast cancer, paclitaxel, patients
Author NameAffiliation
Bora LimThe University of Texas MD Anderson Cancer Center
Simona F ShaitelmanThe University of Texas MD Anderson Cancer Center
Gary J WhitmanThe University of Texas MD Anderson Cancer Center
  • 1 - 3

Datasets

Release 1.2